Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Tang, Xiaowen  [Clear All Filters]
Journal Article
Zhang Y, Liu L, Si Y, Miao M, Qiu H, Tang X, Han Y, Fu C, Jin Z, Chen S, et al. A comparative study of porcine antihuman lymphocyte globulin versus antithymocyte globulin-fresenius in an allogeneic hematopoietic cell transplantation conditioning regimen for severe aplastic anemia. Hematology. 2021;26(1):741-750.
Chu M, Hu S, Shen Y, Shen D, Zhan Y, Fan Y, Chen J, Tang X, Wu D, Xu Y. Comparison of clinical outcomes between peripheral blood stem cells and peripheral blood stem cells plus bone marrow in myelodysplastic syndrome patients with haploidentical transplantation. Bone Marrow Transplant. 2022.
Tian H, Xu Y, Liu L, Yan L, Jin Z, Tang X, Han Y, Fu Z, Qiu H, Sun A, et al. Comparison of outcomes in mixed phenotype acute leukemia patients treated with chemotherapy and stem cell transplantation versus chemotherapy alone. Leuk Res. 2016;45:40-46.
Liu L, Xu G, Zhang Y, Jiao W, Lei M, Zhou H, Wang Q, Qiu H, Tang X, Han Y, et al. Comparison of two different rabbit antithymocyte globulin (r-ATG) preparations:Thymocyte r-ATG versus T lymphoblast cell line r-ATG in allogeneic hematopoietic stem cell transplantation for acquired severe aplastic anemia: propensity score-matched analysi. Biol Blood Marrow Transplant. 2020.
Zhou H, Bao X, Wu X, Tang X, Wang M, Wu D, He J. Donor selection for killer immunoglobulin-like receptors B haplotype of the centromeric motifs can improve the outcome after HLA-identical sibling hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20(1):98-105.
Yu Z, Yao Y, Zhang Y, Chen J, Xu Y, Xue S, Qiu H, Tang X, Han Y, Chen S, et al. The efficacy of first salvage therapy determines the outcomes of adult patients with type 1 primary refractory acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2023.
Valdez BC, Tang X, Li Y, Murray D, Liu Y, Popat U, Champlin RE, Andersson BS. Epigenetic modification enhances the cytotoxicity of busulfan and 4-hydroperoxycyclophosphamide in AML cells. Exp Hematol. 2018.
Liu X, Huang C, Cao X, Yang X, Li S, Jiang S, Lin W, Liu L, Ding X, Tang X, et al. A fully validated flow cytometry method to quantitatively analyze active rATG in human serum and its application in pharmacokinetic study for therapeutic drug monitoring. J Pharm Biomed Anal. 2023;234:115483.
Wu X, Yao Y, Bao X, Zhou H, Tang X, Han Y, Ma X, Liu Y, Chen J, Zhou H, et al. KIR2DS4 and its variant KIR1D are associated with aGVHD, CMV, and OS after sibling-related HLA matched transplantation for patients whose donors belong to the KIR gene haplotype A. Biol Blood Marrow Transplant. 2015.
Xiao H, He Z, Gao Y, Yang Y, Zheng J, Cai Z, Zheng B, Tang X, Guan M. [Mitochondrial tRNA(Thr)T15943C mutation may be a new position that affects the phenotypic expression of deafness associated 12s rRNA A1555G mutation]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2015;32(2):163-168.
Yu Z, Yao Y, Zhang Y, Chen J, Xu Y, Xue S, Qiu H, Tang X, Han Y, Chen S, et al. Outcomes of adult patients with type 1 primary refractory acute myeloid leukemia: a single center experience. Hematology. 2023;28(1):2212534.
Xiao J, Xie J, Zhou B, Liu Y, Lu J, Jiang A, Yao H, Qiu Q, Ding Z, Xue S, et al. RUNX1 together with DAT mutations predicted poor outcome in acute myeloid leukemia. Leuk Lymphoma. 2023:1-11.
Xuan L, Wang Y, Chen J, Jiang E, Gao L, Wu B, Deng L, Liang X, Huang F, Fan Z, et al. Sorafenib therapy is associated with improved outcomes for FLT3-ITD AML relapsing after allo-HSCT. Biol Blood Marrow Transplant. 2019.
Valdez BC, Yuan B, Murray D, Ramdial JLeon, Nieto Y, Popat U, Tang X, Andersson BS. Synergistic cytotoxicity of fludarabine, clofarabine, busulfan, vorinostat and olaparib in AML cells. Front Oncol. 2023;13:1287444.